Skip to main content
Top
Published in: Acta Diabetologica 3/2024

02-11-2023 | Acute Coronary Syndrome | Original Article

The stress hyperglycemic ratio can predict the no-reflow phenomenon following saphenous vein graft intervention in patients with acute coronary syndrome

Authors: Ömer Furkan Demir, Nur Özer Şensoy, Esra Akpınar, Günseli Demir

Published in: Acta Diabetologica | Issue 3/2024

Login to get access

Abstract

Aims

The no-reflow phenomenon (NRP) is a common complication of saphenous vein graft (SVG) interventions. The aim of this study was to investigate the effect of the stress hyperglycemia ratio (SHR) on the development of NRP in patients with acute coronary syndrome (ACS) undergoing percutaneous SVG intervention.

Methods

The study included 223 patients who presented at our center with ACS, had a history of coronary artery bypass graft and underwent a saphenous graft procedure. The relationship between SHR calculated at the time of presentation from glucose and HbA1c values, and the development of NRP evaluated after the procedure with angiography was determined with univariate and multivariate binary regression analysis.

Result

The study population was separated into two groups as those who developed and did not develop NRP. Mean age was determined to be significantly higher in the group that did not develop NRP compared to the group with NRP (p: 0.004). Angiographically, the thrombus burden was determined to be significantly higher in the group that developed NRP (p < 0.001). Patients were separated into 3 tertiles according to the SHR level (T1, T2, T3), and the rate of NRP development was determined at a significantly higher rate in the T3 group (p < 0.001).

Conclusions

This study showed that SHR, a parameter that can be easily calculated noninvasively, is an independent predictor of NRP development in ACS patients undergoing saphenous interventions. In addition, high thrombus burden and predilatation before stenting were also found to be factors that increase the likelihood of developing NRP.
Literature
2.
go back to reference Neumann F-J, Sousa-Uva M, Ahlsson A, ESC Scientific Document Group et al (2019) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 40(02):87–165CrossRefPubMed Neumann F-J, Sousa-Uva M, Ahlsson A, ESC Scientific Document Group et al (2019) 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 40(02):87–165CrossRefPubMed
3.
go back to reference de Vries MR, Simons KH, Jukema JW, Braun J, Quax PH (2016) Vein graft failure: from pathophysiology to clinical outcomes. Nat Rev Cardiol 13(08):451–470CrossRefPubMed de Vries MR, Simons KH, Jukema JW, Braun J, Quax PH (2016) Vein graft failure: from pathophysiology to clinical outcomes. Nat Rev Cardiol 13(08):451–470CrossRefPubMed
4.
go back to reference Harskamp RE, Lopes RD, Baisden CE, de Win-ter RJ, Alexander JH (2013) Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann Surg 257:824–833CrossRefPubMed Harskamp RE, Lopes RD, Baisden CE, de Win-ter RJ, Alexander JH (2013) Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. Ann Surg 257:824–833CrossRefPubMed
5.
go back to reference Lee MS, Park SJ, Kandzari DE et al (2011) Saphenous vein graft intervention. JACC Cardiovasc Interv 4:831–843CrossRefPubMed Lee MS, Park SJ, Kandzari DE et al (2011) Saphenous vein graft intervention. JACC Cardiovasc Interv 4:831–843CrossRefPubMed
6.
go back to reference Soverow J, Lee MS (2014) Saphenous vein graft intervention: status report 2014. J Invasive Cardiol 26:659–667PubMed Soverow J, Lee MS (2014) Saphenous vein graft intervention: status report 2014. J Invasive Cardiol 26:659–667PubMed
7.
go back to reference Salinas P, Jimenez-Valero S, Moreno R et al (2012) Update in pharmacological management of coronary no-reflow phenomenon. Cardiovasc Hematol Agents Med Chem 10:256–264CrossRefPubMed Salinas P, Jimenez-Valero S, Moreno R et al (2012) Update in pharmacological management of coronary no-reflow phenomenon. Cardiovasc Hematol Agents Med Chem 10:256–264CrossRefPubMed
8.
go back to reference Gürbak İ, Panç C, Şahin AA et al (2020) CHA2DS2-VASc score as a predictor of no-reflow phenomenon after saphenous vein graft percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Kardiol Pol 78:1129–1136CrossRefPubMed Gürbak İ, Panç C, Şahin AA et al (2020) CHA2DS2-VASc score as a predictor of no-reflow phenomenon after saphenous vein graft percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Kardiol Pol 78:1129–1136CrossRefPubMed
9.
go back to reference Oswald GA, Corcoran S, Yudkin JS (1984) Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1:1264–1267CrossRefPubMed Oswald GA, Corcoran S, Yudkin JS (1984) Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1:1264–1267CrossRefPubMed
10.
go back to reference Ishihara M, Kagawa E, Inoue I et al (2007) Impact of admission hyperglycemia and diabetes mellitus on short and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol 99:1674–1679CrossRefPubMed Ishihara M, Kagawa E, Inoue I et al (2007) Impact of admission hyperglycemia and diabetes mellitus on short and long-term mortality after acute myocardial infarction in the coronary intervention era. Am J Cardiol 99:1674–1679CrossRefPubMed
11.
go back to reference Eitel I, Hintze S, de Waha S et al (2012) Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction: insights from contrast-enhanced magnetic resonance imaging. Circ Cardiovasc Imaging 5:708–718CrossRefPubMed Eitel I, Hintze S, de Waha S et al (2012) Prognostic impact of hyperglycemia in nondiabetic and diabetic patients with ST-elevation myocardial infarction: insights from contrast-enhanced magnetic resonance imaging. Circ Cardiovasc Imaging 5:708–718CrossRefPubMed
12.
go back to reference Planer D, Witzenbichler B, Guagliumi G et al (2013) Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol 167:2572–2579CrossRefPubMed Planer D, Witzenbichler B, Guagliumi G et al (2013) Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol 167:2572–2579CrossRefPubMed
13.
go back to reference Roberts GW, Quinn SJ, Valentine N et al (2015) Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio. J Clin Endocrinol Metab 100:4490–4497CrossRefPubMed Roberts GW, Quinn SJ, Valentine N et al (2015) Relative hyperglycemia, a marker of critical illness: introducing the stress hyperglycemia ratio. J Clin Endocrinol Metab 100:4490–4497CrossRefPubMed
14.
go back to reference Marenzi G, Cosentino N, Milazzo V et al (2018) Prognostic value of the acute-to-chronic glycemic ratio at admission in acute myocardial infarction: a prospective study. Diabetes Care 41:847–853CrossRefPubMed Marenzi G, Cosentino N, Milazzo V et al (2018) Prognostic value of the acute-to-chronic glycemic ratio at admission in acute myocardial infarction: a prospective study. Diabetes Care 41:847–853CrossRefPubMed
15.
go back to reference Gao S, Liu Q, Ding X et al (2020) Predictive value of the acute-to-chronic glycemic ratio for in-hospital outcomes in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Angiology 71:38–47CrossRefPubMed Gao S, Liu Q, Ding X et al (2020) Predictive value of the acute-to-chronic glycemic ratio for in-hospital outcomes in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention. Angiology 71:38–47CrossRefPubMed
18.
go back to reference Montone RA, Camilli M, Del Buono MG et al (2020) “No-reflow”: update su diagnosi, fisiopatologia e strategie terapeutiche. G Ital Cardiol 21:4S-14S Montone RA, Camilli M, Del Buono MG et al (2020) “No-reflow”: update su diagnosi, fisiopatologia e strategie terapeutiche. G Ital Cardiol 21:4S-14S
19.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470CrossRefPubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470CrossRefPubMed
21.
go back to reference Sianos G, Papafaklis MI, Serruys PW (2010) Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol 22:6B-14BPubMed Sianos G, Papafaklis MI, Serruys PW (2010) Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention. J Invasive Cardiol 22:6B-14BPubMed
22.
go back to reference Thygesen K, Alpert JS, Jaffe AS et al (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40:237–269CrossRefPubMed Thygesen K, Alpert JS, Jaffe AS et al (2019) Fourth universal definition of myocardial infarction (2018). Eur Heart J 40:237–269CrossRefPubMed
23.
go back to reference American Diabetes Association (2018) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 41:S13–S27CrossRef American Diabetes Association (2018) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care 41:S13–S27CrossRef
25.
go back to reference Li X, Hou X, Zhang H et al (2023) Association between stress hyperglycaemia and in-hospital cardiac events after coronary artery bypass grafting in patients without diabetes: a retrospective observational study of 5450 patients. Diabetes Obes Metab 25(Suppl 1):34–42. https://doi.org/10.1111/dom.15013CrossRefPubMed Li X, Hou X, Zhang H et al (2023) Association between stress hyperglycaemia and in-hospital cardiac events after coronary artery bypass grafting in patients without diabetes: a retrospective observational study of 5450 patients. Diabetes Obes Metab 25(Suppl 1):34–42. https://​doi.​org/​10.​1111/​dom.​15013CrossRefPubMed
28.
go back to reference Eid-Lidt G, Gaspar J, Adames AE et al (2010) Long-term outcomes of saphenous vein graft stenting compared with native coronary artery stenting in patients with previous coronary artery bypass graft surgery. Arch Cardiol Mex 80:3–9PubMed Eid-Lidt G, Gaspar J, Adames AE et al (2010) Long-term outcomes of saphenous vein graft stenting compared with native coronary artery stenting in patients with previous coronary artery bypass graft surgery. Arch Cardiol Mex 80:3–9PubMed
29.
go back to reference Hashemi-Jazi M, Hosseini SM, Gholamrezaei A (2017) Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 13:221–229PubMedPubMedCentral Hashemi-Jazi M, Hosseini SM, Gholamrezaei A (2017) Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 13:221–229PubMedPubMedCentral
30.
go back to reference Erkol A, Pala S, Kırma C et al (2011) Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. Am J Cardiol 107:857–862CrossRefPubMed Erkol A, Pala S, Kırma C et al (2011) Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. Am J Cardiol 107:857–862CrossRefPubMed
33.
go back to reference Jean-Philippe Collet and others (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 42(14):1289–1367. https://doi.org/10.1093/eurheartj/ehaa575CrossRef Jean-Philippe Collet and others (2021) 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 42(14):1289–1367. https://​doi.​org/​10.​1093/​eurheartj/​ehaa575CrossRef
34.
go back to reference Özen Y, Bilal ÖM (2023) Assessment of systemic immune-inflammation index as an independent surrogate biomarker of no-reflow phenomenon in acute coronary syndrome patients with coronary artery bypass grafting undergoing percutaneous coronary intervention of saphenous vein graft. Eur Rev Med Pharmacol Sci 27(6):2394–2403. https://doi.org/10.26355/eurrev_202303_31774. (PMID: 37013758)CrossRefPubMed Özen Y, Bilal ÖM (2023) Assessment of systemic immune-inflammation index as an independent surrogate biomarker of no-reflow phenomenon in acute coronary syndrome patients with coronary artery bypass grafting undergoing percutaneous coronary intervention of saphenous vein graft. Eur Rev Med Pharmacol Sci 27(6):2394–2403. https://​doi.​org/​10.​26355/​eurrev_​202303_​31774. (PMID: 37013758)CrossRefPubMed
35.
go back to reference Hashemi-Jazi M, Hosseini SM, Gholamrezaei A (2017) Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 13(5):221–229PubMedPubMedCentral Hashemi-Jazi M, Hosseini SM, Gholamrezaei A (2017) Factors associated with the no-reflow phenomenon following percutaneous intervention of saphenous vein coronary bypass grafts. ARYA Atheroscler 13(5):221–229PubMedPubMedCentral
Metadata
Title
The stress hyperglycemic ratio can predict the no-reflow phenomenon following saphenous vein graft intervention in patients with acute coronary syndrome
Authors
Ömer Furkan Demir
Nur Özer Şensoy
Esra Akpınar
Günseli Demir
Publication date
02-11-2023
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2024
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-023-02201-0

Other articles of this Issue 3/2024

Acta Diabetologica 3/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.